Was Actemra Approved for COVID-19 Treatment?
Actemra (tocilizumab) received Emergency Use Authorization (EUA) from the FDA in June 2021 for hospitalized adults with COVID-19 who require supplemental oxygen or mechanical ventilation. It targets cytokine release syndrome, a severe inflammatory response in COVID patients. The EUA was revoked in February 2023 after the public health emergency ended, as it was no longer justified.[1][2]
How Does Actemra Work Against COVID Inflammation?
Actemra blocks interleukin-6 (IL-6), a protein driving hyperinflammation in severe COVID-19 cases. Clinical trials like RECOVERY showed it reduced mortality by 4% in ventilated patients and 2% in those on oxygen alone, compared to standard care.[3] It's not antiviral— it manages symptoms in critical cases, not mild or preventive use.
Current Status: Still Used for COVID Off-Label?
No full FDA approval for COVID exists post-EUA. Roche, the manufacturer, lists it primarily for rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome from CAR-T therapy. Some hospitals use it off-label for lingering COVID complications, but guidelines like NIH now prioritize antivirals (e.g., Paxlovid) or other immunomodulators for acute cases.[4][5]
Key Trial Results and Who It Helped Most
| Trial | Patients | Key Outcome |
|-------|----------|-------------|
| RECOVERY (2021) | 4,116 severe COVID | 29% lower death risk in ventilated group [3] |
| EMPACTA (2020) | 389, focused on minorities | Faster recovery, no mortality benefit [6] |
| REMAP-CAP (2021) | 803 critically ill | Improved organ support-free days [7] |
It worked best in patients on oxygen or ventilators, not early-stage COVID.
What Are the Risks and Side Effects in COVID Use?
Common issues included infections (8-10% higher risk), liver enzyme elevation, and GI perforation. Trials reported 4-5% serious infections vs. placebo. Not recommended for patients with active infections or low neutrophils.[2][3]
Alternatives for Severe COVID Inflammation Now
- Baricitinib or tofacitinib: JAK inhibitors, FDA-authorized for COVID.
- Dexamethasone: Cheaper steroid, standard for ventilated patients.
- Anakinra: IL-1 blocker, used off-label in some regions.
Actemra remains an option where IL-6 is key, but evidence favors broader steroids first.[4]
Availability, Cost, and Patents
Actemra is subcutaneous or IV; list price ~$1,500-$5,000 per dose depending on form. Patents expire around 2031 in the US, per DrugPatentWatch.com—no COVID-specific exclusivity.[8] Biosimilars are emerging for arthritis but not yet for acute use.
Sources
[1]: FDA EUA Revocation
[2]: FDA Actemra EUA Fact Sheet
[3]: RECOVERY Trial NEJM
[4]: NIH COVID Guidelines
[5]: Roche Actemra Label
[6]: EMPACTA Lancet
[7]: REMAP-CAP JAMA
[8]: DrugPatentWatch Tocilizumab